Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Other Routine +

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

BriaCell Announces ASCO 2026 Data Presentations Amidst Dilution Concerns and Phase 3 Readout Wait

By The Northwire Desk — AI Analysis Apr 27, 2026 · 07:30 BCT · 5.3 BRIACELL THERAPEUTICS CORP. J
Executive Summary
  • Event: Announcement of six clinical data presentations at the 2026 ASCO Annual Meeting (May 29–June 2, 2026).
  • Content: Includes final randomized Phase 2 Bria-IMT™ survival and quality of life data for advanced metastatic breast cancer.
  • Additional Data: Biomarker analyses from ongoing Phase 3 study evaluating predictors of response in metastatic breast cancer.
  • Preceding Context: Follows AACR 2026 presentations (April 20–21, 2026) which covered similar Phase 3 Quality of Life and Phase 2 Biomarker data.
  • Timeline: Abstract publication scheduled for May 21, 2026; conference dates in late May/early June 2026.
Material Impact
  • Expectation vs. Reality: The news is consistent with previous announcements (AACR April 2026) and the company's stated roadmap to present data at major oncology conferences. It does not introduce new clinical results, only confirms their presentation schedule.
  • Market Impact: Likely minimal immediate price impact as this is a "Routine - Positive" announcement rather than a material data release or financing event. The market has already priced in the expectation of ASCO presentations given prior AACR disclosures.
  • Risk Factors: The stock remains sensitive to the Phase 3 top-line data readout expected in H1 2026. This announcement delays actual data scrutiny until May/June, maintaining uncertainty.
  • Comparison to Historical News: Similar to the January 2026 financing news which caused a sharp price drop due to dilution, this news is informational and does not alter the capital structure or clinical risk profile significantly.
BCT · Price
Company Overview
  • Company: BriaCell Therapeutics Corp focuses on cancer immunotherapy, specifically whole-cell-based vaccines and off-the-shelf platforms.
  • Flagship Project: Bria-IMT™ (Bria-ABC Phase 3 trial) in metastatic breast cancer combined with immune checkpoint inhibitors (CPI).
  • Development Stage: Pivotal Phase 3 clinical trials ongoing; FDA Fast Track designation held.
  • Secondary Pipeline:
    • Bria-OTS+ platform (Preclinical/Phase 1/2a): Personalized off-the-shelf immunotherapy for breast and prostate cancer.
    • sCD80 License: Acquired via subsidiary BriaPro (March 2026 transaction).
  • Mechanism: Enhances innate and adaptive immune systems to target tumor cells; utilizes MHC subtyping and biomarker analysis (NLR, DTH) for patient selection.
Read the original news release →

More from BRIACELL THERAPEUTICS CORP. J

Jun 25, 2026 · 07:30

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT(TM)

M&A / Property Jun 02, 2026 · 16:05

BriaCell Closes $4.7M Discounted Offering as Pre-Revenue Burn Rate Demands Cash, Dilution Weighs on Sentiment

Financings Jun 01, 2026 · 07:30

BriaCell’s ASCO Data Validates Pipeline Trajectory, But Dilutive Capital Raise and Phase 3 Event-Driven Timeline Keep Near-Term Upside Capped

Other May 31, 2026 · 19:59

BriaCell Therapeutics Announces Pricing of Offering

Financings May 31, 2026 · 03:20

Briacell prices shares of $4.7M offering at $3.25 each

Financings May 26, 2026 · 07:30

Safety Confirmed but Efficacy Uncertainty Weighs on Valuation Amidst Dilution Concerns

Other